NO20031702L - Nye serinprotease-gener relatert til DPPIV - Google Patents

Nye serinprotease-gener relatert til DPPIV

Info

Publication number
NO20031702L
NO20031702L NO20031702A NO20031702A NO20031702L NO 20031702 L NO20031702 L NO 20031702L NO 20031702 A NO20031702 A NO 20031702A NO 20031702 A NO20031702 A NO 20031702A NO 20031702 L NO20031702 L NO 20031702L
Authority
NO
Norway
Prior art keywords
dppiv
serine protease
genes related
protease genes
novel serine
Prior art date
Application number
NO20031702A
Other languages
English (en)
Other versions
NO20031702D0 (no
NO329842B1 (no
Inventor
Steve Qi
Karen O Akinsanya
J M Pierre Riviere
Jean-Louis Junien
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NO20031702D0 publication Critical patent/NO20031702D0/no
Publication of NO20031702L publication Critical patent/NO20031702L/no
Publication of NO329842B1 publication Critical patent/NO329842B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
NO20031702A 2000-10-12 2003-04-11 Isolert nukleinsyre, antisens oligonukleotid, isolert nukleinsyre, isolert rekombinant polynukleotidmolekyl, ekspresjonsvektor, vertsceller, fremgangsmate for a fremstille et polypeptid, polypeptid samt anvendelse derav, antistoff og fremgangsmate for a lete etter en forbindelse. NO329842B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24011700P 2000-10-12 2000-10-12
PCT/US2001/031874 WO2002031134A2 (en) 2000-10-12 2001-10-12 Novel serine protease genes related to dppiv

Publications (3)

Publication Number Publication Date
NO20031702D0 NO20031702D0 (no) 2003-04-11
NO20031702L true NO20031702L (no) 2003-05-15
NO329842B1 NO329842B1 (no) 2011-01-10

Family

ID=22905181

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031702A NO329842B1 (no) 2000-10-12 2003-04-11 Isolert nukleinsyre, antisens oligonukleotid, isolert nukleinsyre, isolert rekombinant polynukleotidmolekyl, ekspresjonsvektor, vertsceller, fremgangsmate for a fremstille et polypeptid, polypeptid samt anvendelse derav, antistoff og fremgangsmate for a lete etter en forbindelse.

Country Status (17)

Country Link
US (2) US6844180B2 (no)
EP (1) EP1346033A2 (no)
JP (1) JP2004528812A (no)
KR (1) KR100875221B1 (no)
CN (2) CN100354417C (no)
AU (2) AU2002213138B2 (no)
CA (1) CA2425001A1 (no)
CZ (1) CZ20031301A3 (no)
HU (1) HUP0301356A3 (no)
IL (2) IL155245A0 (no)
MX (1) MXPA03003191A (no)
NO (1) NO329842B1 (no)
NZ (1) NZ525443A (no)
PL (1) PL366005A1 (no)
RU (1) RU2305133C2 (no)
WO (1) WO2002031134A2 (no)
ZA (1) ZA200303306B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
JP4748908B2 (ja) * 1999-09-10 2011-08-17 ザ・ユニバーシティ・オブ・シドニー ジペプチジルペプチダーゼ
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
AUPR107800A0 (en) * 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
GB0101760D0 (en) * 2001-01-23 2001-03-07 Glaxo Group Ltd Novel protein
AU2002249453A1 (en) * 2001-04-24 2002-11-05 Isis Innovation Ltd Enzyme and snp marker for disease
CA2446806A1 (en) 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
US6709651B2 (en) * 2001-07-03 2004-03-23 B.M.R.A. Corporation B.V. Treatment of substance P-related disorders
EP1466016A2 (en) * 2002-01-09 2004-10-13 Riken Institute Of Physical And Chemical Research Cancer profiles
ATE394118T1 (de) 2002-08-09 2008-05-15 Prosidion Ltd Dipeptidyl peptidase iv inhibitoren zur senkung der chronische gewichtszunahme
EP1608317B1 (en) 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EA013427B1 (ru) 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
EP1745293A1 (en) * 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 9 (dpp9)
WO2005106021A1 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 8 (dpp8)
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
US7872124B2 (en) * 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP5027137B2 (ja) 2005-09-14 2012-09-19 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤の投与
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
JP5242402B2 (ja) * 2005-10-11 2013-07-24 アマノ エンザイム ユーエスエー カンパニー，リミテッド Ｐａｉ−１の酵素阻害物質
EP1971614A1 (en) 2005-11-14 2008-09-24 Probiodrug AG Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7728146B2 (en) 2006-04-12 2010-06-01 Probiodrug Ag Enzyme inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101259119B (zh) * 2007-03-08 2010-05-19 上海市计划生育科学研究所 一种丝氨酸蛋白酶抑制剂及其衍生物在生育调节中的应用
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2014068023A1 (en) * 2012-11-02 2014-05-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Dpp8 and dpp9 peptide inhibitors
MX2021011726A (es) * 2019-03-26 2021-10-22 Encodia Inc Escindasas modificadas, usos de las mismas y kits relacionados.
US11427814B2 (en) 2019-03-26 2022-08-30 Encodia, Inc. Modified cleavases, uses thereof and related kits

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
AU2501200A (en) 1999-01-11 2000-08-01 Incyte Pharmaceuticals, Inc. Human peptidases
WO2000058473A2 (en) 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
JP4748908B2 (ja) 1999-09-10 2011-08-17 ザ・ユニバーシティ・オブ・シドニー ジペプチジルペプチダーゼ
CN1307128A (zh) * 2000-01-26 2001-08-08 上海博道基因技术有限公司 一种新的多肽——人二肽氨肽酶28和编码这种多肽的多核苷酸
JP2004515217A (ja) * 2000-06-16 2004-05-27 インサイト・ゲノミックス・インコーポレイテッド プロテアーゼ

Also Published As

Publication number Publication date
EP1346033A2 (en) 2003-09-24
US20050059081A1 (en) 2005-03-17
HK1078104A1 (zh) 2006-03-03
WO2002031134A3 (en) 2003-07-17
NO20031702D0 (no) 2003-04-11
CA2425001A1 (en) 2002-04-18
ZA200303306B (en) 2004-08-12
US6844180B2 (en) 2005-01-18
IL155245A0 (en) 2003-11-23
NO329842B1 (no) 2011-01-10
MXPA03003191A (es) 2004-12-03
CN100354417C (zh) 2007-12-12
KR100875221B1 (ko) 2008-12-19
HUP0301356A2 (hu) 2003-10-28
US20020115843A1 (en) 2002-08-22
IL155245A (en) 2010-04-15
CN1636061A (zh) 2005-07-06
CZ20031301A3 (cs) 2003-10-15
WO2002031134A2 (en) 2002-04-18
HUP0301356A3 (en) 2010-03-29
NZ525443A (en) 2006-04-28
RU2305133C2 (ru) 2007-08-27
KR20030038815A (ko) 2003-05-16
AU1313802A (en) 2002-04-22
US7157241B2 (en) 2007-01-02
AU2002213138B2 (en) 2006-07-20
JP2004528812A (ja) 2004-09-24
PL366005A1 (en) 2005-01-24
CN101270362A (zh) 2008-09-24

Similar Documents

Publication Publication Date Title
NO20031702D0 (no) Nye serinprotease-gener relatert til DPPIV
IL155202A0 (en) Biaryl compounds as serine protease inhibitors
DE60138717D1 (de) Peptidomimetika als protease inhibitoren
DE60237161D1 (de) Sse einzuschlagen
DE60134094D1 (de) C7-taxanester als antitumormittel
ATE299970T1 (de) Wasserarmatur
DE50113294D1 (de) Hochselektive inhibitoren des urokinase-plasminogenaktivators
NO20025998D0 (no) Stentekspansjon forårsaket av to ballonger
NO20030274D0 (no) Nye aryleten-sulfonamider
EP1226150A4 (en) TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA
EP1594845A4 (en) BENZENE ACETAMIDE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS
DE60144430D1 (de) Subtilase varianten
NO20025005D0 (no) Proteaseinhibitorer
AU2003292406A8 (en) Serine protease
EP1427439A4 (en) GAMMA-THREE PROTEASE
DE10196261T1 (de) Überwachungsanordnung
FR2809043B1 (fr) Lance thermo-abrasive
DE50114913D1 (de) Überflurwassersäule
EP1544304A4 (en) NEW SERINPROTEASE
ATA80032002A (de) Mechanischer hammer
NO20030809D0 (no) Nytt proteasegen
ITMI20010863A0 (it) Bocchello di un estrusore a vite o affini per produrre mattoni foratidi traverso
ITRM20000005A0 (it) Giocattolo per formare bolle di grandi dimensioni.
DE50112417D1 (de) Kraftwerksanlage
FI20002837A0 (fi) Hiontamenetelmä

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees